DK1720571T3 - Fremgangsmåde til behandling af hæmolytisk sygdom - Google Patents

Fremgangsmåde til behandling af hæmolytisk sygdom

Info

Publication number
DK1720571T3
DK1720571T3 DK05712607.0T DK05712607T DK1720571T3 DK 1720571 T3 DK1720571 T3 DK 1720571T3 DK 05712607 T DK05712607 T DK 05712607T DK 1720571 T3 DK1720571 T3 DK 1720571T3
Authority
DK
Denmark
Prior art keywords
treatment
haemolytic disease
haemolytic
disease
Prior art date
Application number
DK05712607.0T
Other languages
Danish (da)
English (en)
Inventor
Russell P Rother
Leonard Bell
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34808492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1720571(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of DK1720571T3 publication Critical patent/DK1720571T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05712607.0T 2004-02-03 2005-02-03 Fremgangsmåde til behandling af hæmolytisk sygdom DK1720571T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/771,552 US20050169921A1 (en) 2004-02-03 2004-02-03 Method of treating hemolytic disease
PCT/US2005/003225 WO2005074607A2 (en) 2004-02-03 2005-02-03 Method of treating hemolytic disease

Publications (1)

Publication Number Publication Date
DK1720571T3 true DK1720571T3 (da) 2012-09-03

Family

ID=34808492

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05712607.0T DK1720571T3 (da) 2004-02-03 2005-02-03 Fremgangsmåde til behandling af hæmolytisk sygdom

Country Status (16)

Country Link
US (5) US20050169921A1 (enExample)
EP (7) EP2522364A1 (enExample)
JP (5) JP2007520494A (enExample)
KR (1) KR101197799B1 (enExample)
CN (4) CN103977402A (enExample)
AU (1) AU2005209854B2 (enExample)
CA (1) CA2554632A1 (enExample)
CY (1) CY1113190T1 (enExample)
DK (1) DK1720571T3 (enExample)
ES (1) ES2389093T3 (enExample)
IL (2) IL177003A0 (enExample)
NZ (1) NZ549328A (enExample)
PL (1) PL1720571T3 (enExample)
PT (1) PT1720571E (enExample)
SI (1) SI1720571T1 (enExample)
WO (1) WO2005074607A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
ES2614274T3 (es) * 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
NZ551308A (en) * 2004-05-14 2009-06-26 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006107708A1 (en) * 2005-04-04 2006-10-12 Alexion Pharmaceuticals, Inc. Treatment of disease caused by excess free hemoglobin
PT2500030E (pt) * 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
AU2007224250B2 (en) * 2006-03-02 2012-05-03 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
ES2965283T3 (es) * 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
PL2907827T3 (pl) * 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US9447176B2 (en) * 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
AU2010306581B2 (en) * 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US20110124019A1 (en) * 2009-11-25 2011-05-26 The Charlotte-Mecklenburg Hospital Authority Method of using carbonic anhydrase to detect hemolysis
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
BR112012022917A2 (pt) * 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
AU2015230852B2 (en) * 2011-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. High concentration antibody formulations
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN107638565B (zh) * 2011-04-08 2021-12-21 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的状况的方法
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
WO2013137912A2 (en) * 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
SMT201800253T1 (it) * 2012-04-06 2018-07-17 Omeros Corp Composizioni e metodi per inibire masp-1 e/o masp-3 per il trattamento di emoglobinuria parossistica notturna
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
EP3473272A1 (en) * 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107428823B (zh) 2015-01-22 2021-10-26 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2016160756A2 (en) * 2015-03-31 2016-10-06 Alexion Pharmaceuticlas, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
IT201600121482A1 (it) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme
CR20190403A (es) 2017-01-31 2019-10-10 Hoffmann La Roche Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
IL280475B2 (en) 2018-08-01 2026-04-01 Chugai Pharmaceutical Co Ltd Pharmaceutical preparation for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease
CN115068604A (zh) 2019-07-31 2022-09-20 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
CA3144921A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5650825A (en) * 1995-03-31 1997-07-22 Matsushita Electric Corporation Of America Method and apparatus for sending private data instead of stuffing bits in an MPEG bit stream
DE19826743A1 (de) * 1998-06-16 1999-12-23 Bayer Ag Verfahren zur Herstellung von geträgerten Polymerisationskatalysatorsystemen und Verwendung dieser zur Homo- und Copolymerisation ungesättigter Monomere
AU2002234001B2 (en) * 2000-12-05 2008-05-01 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
WO2003081206A2 (en) * 2002-03-18 2003-10-02 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease

Also Published As

Publication number Publication date
AU2005209854A1 (en) 2005-08-18
JP5873047B2 (ja) 2016-03-01
PL1720571T3 (pl) 2012-11-30
EP2910253A1 (en) 2015-08-26
EP2522362A1 (en) 2012-11-14
IL240410A0 (en) 2015-09-24
CA2554632A1 (en) 2005-08-18
SI1720571T1 (sl) 2012-10-30
KR20070009996A (ko) 2007-01-19
JP2011126917A (ja) 2011-06-30
EP1720571B1 (en) 2012-06-13
ES2389093T3 (es) 2012-10-23
US20050191298A1 (en) 2005-09-01
JP2007520494A (ja) 2007-07-26
WO2005074607A2 (en) 2005-08-18
EP1720571B9 (en) 2012-10-24
NZ549328A (en) 2010-12-24
JP2017057234A (ja) 2017-03-23
US20120308559A1 (en) 2012-12-06
EP2520311A3 (en) 2012-11-14
EP1720571A4 (en) 2008-11-19
CN103977402A (zh) 2014-08-13
CY1113190T1 (el) 2016-04-13
US20110086040A1 (en) 2011-04-14
US20050169921A1 (en) 2005-08-04
CN103977403A (zh) 2014-08-13
KR101197799B1 (ko) 2012-11-05
EP1720571A2 (en) 2006-11-15
EP2520311A2 (en) 2012-11-07
EP2522361A1 (en) 2012-11-14
HK1094950A1 (en) 2007-04-20
CN103446584A (zh) 2013-12-18
KR101197799B9 (ko) 2024-02-08
EP2522364A1 (en) 2012-11-14
CN1938047A (zh) 2007-03-28
PT1720571E (pt) 2012-08-29
EP2522363A1 (en) 2012-11-14
IL177003A0 (en) 2006-12-10
JP2013213044A (ja) 2013-10-17
AU2005209854B2 (en) 2011-01-20
WO2005074607A3 (en) 2006-09-14
US20100068202A1 (en) 2010-03-18
JP2015083611A (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DE602005015234D1 (de) Zusammensetzungen zur wäschebehandlung
DE602005014252D1 (de) Zusammensetzungen zur wäschebehandlung
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
DE602005010597D1 (de) Bildaufzeichnungsverfahren
DK1611108T3 (da) Fremgangsmåde til fremstilling af telmisartan
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
NO20076030L (no) Fremgangsmåte for fremstilling av hydroklorsilaner
DK1813678T3 (da) Fremgangsmåde til fremstilling af glycogen
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
EP1765735A4 (en) SLUDGE TREATMENT PROCESS
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1814555T3 (da) S-mirtazapin til behandling af hedeture
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
DK1805316T3 (da) Fremgangsmåde til fremstilling af de enantiomere former af cis-3-hydroxycy-
DK1812002T3 (da) Behandling af mastitis